Analysis for C24H25N7O2S2 (507.63); calculated: C, ABT-263 clinical trial 56.78; H, 4.96; N, 19.31; S, 12.63; found: C, 56.80; H, 4.97; N, 19.34; S, 12.66. IR (KBr), ν (cm−1): 3100 (OH), 3069 (CH aromatic), 2962 (CH aliphatic), 1715 (C=O), 1611 (C=N), 1514 (C–N), 1367 (C=S), 692 (C–S). 1H NMR (DMSO-d 6) δ (ppm): 1.66–1.72 (m, 4H, 2CH2), 2.29 (t, J = 5 Hz, 2H, CH2), 2.68 (t, J = 5 Hz, 2H, CH2), 4.27 (s, 2H, CH2), 4.58 (s, 2H, CH2), 4.69 (s, 2H, CH2), 7.47–8.08 (m, 10H, 10ArH), 13.68 (s, 1H,

OH). 5-[(4,5-Diphenyl-4H-1,2,4-triazol-3-yl)sulfanyl]methyl-2-(pyrrolidin-1-ylmethyl)-2,4-dihyro-3H-1,2,4-triazole-3-thione (12) To a solution of 10 mmol of compound 10 in ethanol, pyrrolidine (10 mmol) and formaldehyde (0.2 mL) were added. The mixture was stirred for 2 h at room temperature. After that, distilled water was added and the precipitate that formed was filtered, washed with distilled water, and check details crystallized from ethanol. Yield: 74.8 %, mp: 224–226 °C (dec.). Analysis for C22H23N7S2 (449.59); LY3023414 ic50 calculated:

C, 58.77; H, 5.16; N, 21.81; S, 14.26; found: C, 58.79; H, 5.14; N, 21.83; S, 12.24. IR (KBr), ν (cm−1): 3290 (NH), 3098 (CH aromatic), 2978, 1482 (CH aliphatic), 1623 (C=N), 1522 (C–N), 1341 (C=S), 685 (C–S). 1H NMR (DMSO-d 6) δ (ppm): 1.67–1.73 (m, 4H, 2CH2), 2.32 (t, J = 5 Hz, 2H, CH2), 2.77 (t, J = 5 Hz, 2H, CH2), 4.05 (s, 2H, CH2), 4.68 (s, 2H, CH2), 7.36–8.35 (m, 10H, 10ArH), 14.68 (brs, 1H, NH). Microbiology Materials and methods All synthesized compounds were preliminarily tested for their in vitro antibacterial activity against Gram-positive and -negative reference bacterial strains and next by the broth

microdilution method against the selected bacterial strains. Panel reference strains of aerobic bacteria from the American Type Culture Collection, including six Gram-positive bacteria, S. aureus ATCC 25923, S. aureus ATCC 6538, S. epidermidis ATCC 12228, B. subtilis ATCC 6633, B. cereus ATCC 10876, M. luteus ATCC 10240, and four Gram-negative bacteria, Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 13883, Proteus mirabilis ATCC 12453, Pseudomonas aeruginosa ATCC 9027, were used. Microbial suspensions with an optical density of 0.5 McFarland standard 150 × 106 CFU/mL (CFUs—colony forming units) were prepared in sterile 0.85 % NaCl. All stock solutions Edoxaban of the tested compounds were prepared in DMSO. The medium with DMSO at the final concentration and without the tested compounds served as the control—no microbial growth inhibition was observed. Preliminary antimicrobial potency in vitro of the tested compounds was screened using the agar dilution method on the basis of the bacterial growth inhibition on the Mueller–Hinton agar containing the compounds at a concentration of 1,000 μg/mL. The plates were poured on the day of testing. 10 μL of each bacterial suspension was put onto the prepared solid media.